Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
BioVaxys Technology ( (TSE:BIOV) ) has issued an announcement.
BioVaxys Technology Corp. is developing its DPX™ platform as a superior alternative to lipid nanoparticles (LNPs) for packaging and delivering mRNA vaccines. The company’s DPX technology has been shown to provide enhanced stability and targeted immune response, addressing the limitations of LNPs, such as adverse reactions and instability. This development positions BioVaxys as a key player in the mRNA vaccine market, which is projected to grow significantly by 2030, and has generated interest from potential partners in the field.
More about BioVaxys Technology
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in novel immunotherapies based on its DPX™ immune-educating technology platform and HapTenix© ‘neoantigen’ tumor cell construct platform. The company focuses on treating cancers, infectious diseases, and other immunological conditions. Its clinical stage pipeline includes therapies for advanced cancers and immunotherapies for allergies.
YTD Price Performance: -14.00%
Average Trading Volume: 540,298
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $10.71M
See more data about BIOV stock on TipRanks’ Stock Analysis page.
